文献速递血脂与心血管预防冠心病

无标准可改变危险因素女性的C反应蛋白与心血管风险

C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the 'SMuRF-less but inflamed'.
PubMed 文献 · Eur Heart J · 2026-01-01

在12 530名无高血压、血脂异常、糖尿病和吸烟的美国健康女性中,基线高敏C反应蛋白(hsCRP)升高与30年内心血管事件风险增加相关。hsCRP最高五分位者冠心病风险是最低五分位的2.23倍,hsCRP>3 mg/L者冠心病风险比<1 mg/L者高77%。

要点

  • 无标准可改变危险因素女性中,hsCRP升高仍可识别心血管高风险人群。
  • hsCRP每增加一个五分位,30年冠心病风险增加21%。
  • hsCRP>3 mg/L者冠心病风险比<1 mg/L者高77%。

核心结论

  • 在无标准可改变危险因素的女性中,hsCRP升高与长期心血管事件风险增加独立相关。

研究设计与样本

  • 基于NIH资助的女性健康研究前瞻性队列,纳入12 530名无标准可改变危险因素的初始健康美国女性,随访30年。

主要发现

  • 随访30年共发生973例首次主要心血管事件。
  • 发生心血管事件者基线hsCRP中位数显著高于未发生者(2.22 vs 1.50 mg/L,P < .0001)。
  • 年龄校正后,hsCRP最低至最高五分位的冠心病HR分别为1.0、1.24、1.41、1.57、2.23(P-trend < .0001)。
  • hsCRP最高vs最低五分位的缺血性卒中HR为1.69(95% CI 1.16-2.47),总心血管事件HR为1.74(95% CI 1.42-2.14)。
  • hsCRP>3 mg/L者相比<1 mg/L者,冠心病风险高77%,缺血性卒中风险高39%,总心血管事件风险高52%。

关键数值与推荐

  • hsCRP每增加一个五分位,年龄校正冠心病HR为1.21(95% CI 1.13-1.29,P < .0001)。
  • 进一步校正BMI和eGFR后,最高vs最低五分位冠心病HR为1.86(95% CI 1.35-2.58,P = .0002)。
  • 进一步校正BMI和eGFR后,hsCRP>3 mg/L vs <1 mg/L的冠心病HR为1.52(95% CI 1.20-1.92,P = .0006)。

临床怎么用

  • 对无标准可改变危险因素的女性,可考虑检测hsCRP以识别残留炎症风险。
  • hsCRP>3 mg/L的无标准可改变危险因素女性可能从他汀治疗中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Interventions in preventive cardiology traditionally focus on four standard modifiable cardiovascular risk factors (SMuRFs): hypertension, dyslipidaemia, diabetes mellitus, and smoking. Yet, a substantial proportion of incident cardiovascular events accrues for individuals with none of these factors, particularly among women for whom cardiovascular disease remains under-detected and under-treated. The utility of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) was evaluated to detect cardiovascular risk in SMuRF-less women participating in the prospective NIH-funded Women's Health Study. METHODS: High-sensitivity C-reactive protein was measured at baseline among 12 530 initially healthy American women with no standard modifiable risk factors who were followed over 30 years for first major adverse cardiovascular events (myocardial infarction, coronary revascularization, ischaemic stroke, or cardiovascular death). Hazard ratios (HRs) and 95% confidence intervals (95% CI) for incident coronary heart disease (CHD), ischaemic stroke, and total cardiovascular events were calculated across quintiles of hsCRP, along with 30-year cumulative incidence curves. Hazard ratios were also computed according to common clinical thresholds of hsCRP, according to standard deviation change in hsCRP, and as a continuous variable in penalized spline regression models. RESULTS: During 30-year follow-up, 973 first major cardiovascular events accrued. Median baseline hsCRP was significantly higher among SMuRF-less women who subsequently suffered a cardiovascular event when compared with those who did not (median hsCRP 2.22 vs 1.50 mg/L, P < .0001). In age-adjusted analyses, the HRs for the primary endpoint of incident CHD from lowest (referent) to highest levels of hsCRP at study entry were 1.0 (referent), 1.24, 1.41, 1.57, and 2.23 (P-trend < .0001) such that CHD risk over 30 years increased 21% for each increasing quintile of hsCRP (age-adjusted HR 1.21, 95% CI 1.13-1.29, P < .0001). Corresponding HRs for the top vs bottom quintile of hsCRP were 1.69 (95% CI 1.16-2.47) for ischaemic stroke and 1.74 (95% CI 1.42-2.14) for total cardiovascular disease events. Using common clinical hsCRP thresholds, SMuRF-less women with hsCRP > 3 mg/L had a 77% higher risk of CHD events, a 39% higher risk of ischaemic stroke events, and a 52% higher risk of total cardiovascular disease events when compared with those with hsCRP < 1 mg/L. Spline analyses demonstrated linear association with risk across the spectrum of hsCRP values. Hazards were moderately attenuated after additional adjustment for body mass index and estimated glomerular filtration rate [covariate-adjusted CHD HR 1.86 (95% CI 1.35-2.58, P = .0002) for comparison of the top vs bottom quintile of hsCRP and 1.52 (95% CI 1.20-1.92, P = .0006) for comparison of those with hsCRP > 3 mg/L to those < 1 mg/L]. CONCLUSIONS: Over a 30-year horizon, cardiovascular events commonly occur among 'SMuRF-less but inflamed' women who are otherwise missed by current screening algorithms, a clinically important observation given recent trial data demonstrating that statin therapy reduces risk by 38% among such individuals.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ridker PM, Figtree GA, Moorthy MV, et al. C-reactive protein and cardiovascular risk among women with no standard modifiable risk factors: evaluating the 'SMuRF-less but inflamed'. Eur Heart J. 2026. PMID: 40878356. doi:10.1093/eurheartj/ehaf658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。